Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib rollover continuation study
2014-003527-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib in cancer, sponsored by Novartis. Primary endpoint: Number of patients receiving ruxolitinib. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2014-003527-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003527-22.